Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Artificial intelligence has been a mainstay of the Radiological Society of North America (RSNA) annual meeting for nearly a decade. Each year brings new developments, reveals new capabilities and algorithms, and furthers the conversation about how these tools can help radiologists provide care.
This year, the conversation began to turn to what steps could come next for AI. Conversations about deployment, consolidation, and U.S. Food & Drug Administration clearance are now the norm as the technology becomes less of a novelty and more of a mainstay.
In this episode of The Reading Room, Diagnostic Imaging speaks with Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, about her reaction to what this year’s conference offered about these tools and what she sees on the horizon in 2021.
For additional RSNA coverage, click here.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
FDA Clears AI-Powered Qualitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.
New Literature Review Finds ChatGPT Effective in Radiology in 84 Percent of Studies
April 29th 2024While noting a variety of pitfalls with the chatbot ranging from hallucinations to improper citations, the review authors found the use of ChatGPT in radiology demonstrated “high performance” in 37 out of 44 studies.